Komzifti Patient Assistance Program

(ziftomenib)

Key Takeaways

  1. Komzifti™ (ziftomenib) is a prescription targeted cancer therapy approved for certain adults with relapsed or refractory acute myeloid leukemia (AML) that has a susceptible NPM1 mutation.
  2. Komzifti is the first FDA-approved menin inhibitor for this specific type of AML. It is intended for patients who have no satisfactory alternative treatment options.
  3. Komzifti carries an FDA Boxed Warning for differentiation syndrome, a potentially life-threatening complication that requires immediate medical attention.
  4. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Komzifti more affordable.

Introduction

Acute myeloid leukemia (AML) is an aggressive blood cancer that often requires intensive treatment. Unfortunately, some patients experience relapse after treatment or develop leukemia that no longer responds to available therapies. For individuals whose AML contains a susceptible NPM1 mutation, targeted therapies have created new treatment options that were not previously available.

Komzifti is an oral targeted therapy approved for adults with relapsed or refractory AML who have a susceptible NPM1 mutation confirmed by an appropriate diagnostic test and who have no satisfactory alternative treatment options.

Access to prescription assistance programs through Prescription Hope may help eligible patients obtain Komzifti at a more affordable cost.

What Is the Komzifti Patient Assistance Program?

Understanding Komzifti Prescription Assistance

While researching how to find affordable Komzifti, some patients may have come across the Komzifti patient assistance program.

Patient assistance programs have been introduced by many pharmaceutical manufacturers to help their qualified patients afford the name-brand medication their treatment requires at a lower cost than market rate. Patients must meet certain criteria such as insurance coverage, income, and residency to qualify.

However, these patient assistance programs have been known to be difficult and frustrating to apply for. But Prescription Hope can help.

How Expert Advocates Help Make Komzifti More Affordable

Personalized Medication Assistance

Prescription Hope is proud to offer leukemia medication support, both in the form of Komzifti application help and ongoing patient support services. Our team of prescription assistance specialists strives to help qualified patients both with Komzifti enrollment assistance and even after acceptance into the medication assistance program, assisting you with tasks such as form completion, document and signature collection, dispute advocacy and support, and more.

Ongoing Patient Support

After approval, qualified patients under Prescription Hope receive specialty oncology support and long-term medication assistance. Our team keeps up with any administrative work needed for our qualified patients to be able to keep their accepted status in a patient support program, such as document updates, yearly renewals, program monitoring, and other tasks so that you can focus on treatment.

Komzifti Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$47,382.70

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating AML Treatment Costs

Prescription Hope can assist qualified patients with access to their brand-name medication at a monthly rate of $70.00 per month, per medication.

If we can’t find a way for you to save, you pay us nothing!

Komzifti Patient Assistance Eligibility

General Eligibility Requirements

Medication assistance requirements differ for each patient assistance program. Enroll with Prescription Hope to properly determine Komzifti patient assistance qualifications. However, all patient assistance programs look at Komzifti eligibility based on several different categories. Some of those include:

Income: All programs have different requirements for what the patient’s income status is.

Insurance: Requirements for insurance coverage also vary depending on the program.

Prescription: Patients must hold a valid prescription for the medication they are seeking.

U.S. Residency: Any patients wishing to qualify must be legal U.S. citizens.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Do you need help with the Komzifti application process? Prescription Hope offers prescription support services in 6 easy steps:

  1. Submit Information: Our online enrollment form only takes a few minutes to complete.
  2. Advocate Contact: Our patient advocates will contact you in 1-2 business days after we get your form.
  3. Document Collection: Our team will coordinate with you to obtain all necessary documents after prequalification.
  4. Provider Coordination: We will coordinate with your healthcare provider to get any needed signatures.
  5. Program Submission: We will make sure everything is in order and submit your application for you, all while keeping in touch with the pharmaceutical manufacturer.
  6. Medication Delivery: Following approval, qualified patients will normally receive their medication in 2 weeks directly to their door or doctor’s office.

Understanding Komzifti

How Komzifti Works

Komzifti works by blocking menin, a protein that interacts with genetic pathways responsible for leukemia cell growth.

In AML with a susceptible NPM1 mutation, the interaction between menin and mutant NPM1 helps leukemia cells remain immature and continue multiplying. By inhibiting menin, Komzifti disrupts these signals, allowing leukemia cells to mature normally or die, helping reduce the leukemia burden.

Because Komzifti specifically targets leukemia with a susceptible NPM1 mutation, patients must undergo molecular testing before starting treatment.

What Conditions Does Komzifti Treat?

Komzifti is FDA-approved for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who:

  • Have a susceptible nucleophosmin 1 (NPM1) mutation confirmed by an appropriate diagnostic test
  • Have no satisfactory alternative treatment options

Komzifti received FDA Priority Review, Breakthrough Therapy Designation, and Orphan Drug Designation before its approval.

Benefits of Treatment

For eligible patients with relapsed or refractory AML, Komzifti may:

  • Induce remission in eligible patients
  • Reduce the number of leukemia cells
  • Improve normal blood cell production by restoring healthier bone marrow function
  • Reduce or eliminate the need for red blood cell and platelet transfusions in some patients
  • Provide a targeted oral treatment option for patients with limited therapeutic alternatives

Treatment outcomes vary, and continued therapy depends on treatment response and tolerability. Clinical trials demonstrated complete remission (CR) or complete remission with partial hematologic recovery (CRh) in a subset of treated patients, with some patients also achieving transfusion independence.

Important Safety Information and Side Effects

Komzifti carries an FDA Boxed Warning for Differentiation Syndrome.

Differentiation syndrome can be serious or fatal. If differentiation syndrome is suspected, Komzifti should be interrupted, and corticosteroid treatment should be started promptly with appropriate hemodynamic and laboratory monitoring. Treatment may be resumed after symptoms improve according to the FDA-approved prescribing information.

The most commonly reported side effects include:

  • Infection without an identified pathogen
  • Bleeding (hemorrhage)
  • Diarrhea
  • Nausea
  • Fatigue
  • Swelling (edema)
  • Bacterial infections
  • Constipation
  • Fever
  • Muscle or bone pain

Common laboratory abnormalities include:

  • Low platelet counts (thrombocytopenia)
  • Low white blood cell counts (neutropenia)
  • Low red blood cell counts (anemia)
  • Increased liver enzyme levels
  • Electrolyte abnormalities

Patients should notify their healthcare provider if side effects become severe or persistent.

Komzifti may also prolong the QT interval, increasing the risk of serious heart rhythm abnormalities. Healthcare providers should monitor electrocardiograms (ECGs), potassium, and magnesium levels and correct electrolyte abnormalities before treatment whenever possible. Patients should immediately report dizziness, fainting, or rapid or irregular heartbeat.

Komzifti may cause fetal harm during pregnancy. Females who can become pregnant should use effective contraception during treatment and for the recommended period after the last dose. Male patients with partners who can become pregnant should also follow contraception recommendations provided by their healthcare provider.

It is not known whether ziftomenib passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment and for the recommended period after the last dose.

Komzifti may interact with:

  • Proton pump inhibitors (PPIs)
  • H2-receptor antagonists
  • Antacids
  • Strong or moderate CYP3A inhibitors
  • Strong or moderate CYP3A inducers
  • Prescription medications
  • Over-the-counter medicines
  • Vitamins
  • Herbal supplements

Patients should review all medications with their healthcare provider before starting treatment.

Komzifti is taken orally once daily and may be taken with or without food. Capsules should be swallowed whole and should not be opened, crushed, or chewed. Treatment continues until disease progression or unacceptable toxicity occurs. Patients should also follow prescribing recommendations regarding the timing of acid-reducing medications because these products can affect ziftomenib absorption.

Healthcare providers routinely monitor:

  • Complete blood counts (CBCs)
  • Electrocardiograms (ECGs)
  • Electrolytes
  • Liver function
  • Signs and symptoms of differentiation syndrome

throughout treatment.

Access to Multiple Medications

Support Beyond Komzifti

Patients undergoing cancer treatment are often in need of multiple medication assistance programs, due to the cost and severity of treatment.

Prescription Hope helps qualified patients gain access to their specialty oncology medications so they can focus on treatment and the things that matter, like time with their loved ones. We offer the same service for hundreds of brand-name medications, so every medication a patient qualifies for simply costs $70.00 per month, per medication.

Why Choose Prescription Hope for Komzifti Assistance

Patient-Focused Medication Support

Since 2006, Prescription Hope has offered patient-centered prescription help to qualified patients across America. We are glad to offer you Komzifti assistance through Prescription Hope.

Simplified Access to Specialty Medications

Prescription Hope offers prescription assistance help at the low monthly fee of $70.00 per month, per medication. There are no hidden fees, add-ons, long contracts, or medication costs.

Ongoing Prescription Assistance

Even after your application to a patient assistance program is accepted, our team will continue to keep track of all your administrative needs related to prescription affordability programs. We manage refill scheduling, document updates, yearly renewals, and more.

Network Access

Our network has hundreds of brand-name medications and their associated patient assistance programs. From rural areas to big cities, Prescription Hope is honored to assist you with long-term medication support you can count on.

If you are in need of Komzifti and don’t know how you’re going to afford it, enroll with Prescription Hope so we can help you save money now!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!